Cargando…

Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway

PURPOSE: To explore the mechanism of levonorgestrel (LNG)-ameliorating adenomyosis through long non-coding RNA H19 (lncRNA H19)/miR-17/Toll-like receptor 4 (TLR4) pathway. PATIENTS AND METHODS: A total of 71 cases of adenomyosis and 54 cases of normal endometrium were sampled. Quantitative polymeras...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Na, Zhang, Wenfeng, Wang, Hongjiang, Shi, Wei, Wang, Li, Ma, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457840/
https://www.ncbi.nlm.nih.gov/pubmed/32921982
http://dx.doi.org/10.2147/DDDT.S248095
_version_ 1783576077648527360
author Liang, Na
Zhang, Wenfeng
Wang, Hongjiang
Shi, Wei
Wang, Li
Ma, Lijuan
author_facet Liang, Na
Zhang, Wenfeng
Wang, Hongjiang
Shi, Wei
Wang, Li
Ma, Lijuan
author_sort Liang, Na
collection PubMed
description PURPOSE: To explore the mechanism of levonorgestrel (LNG)-ameliorating adenomyosis through long non-coding RNA H19 (lncRNA H19)/miR-17/Toll-like receptor 4 (TLR4) pathway. PATIENTS AND METHODS: A total of 71 cases of adenomyosis and 54 cases of normal endometrium were sampled. Quantitative polymerase chain reaction (qPCR) was employed to quantify lncRNA H19, miR-17, and TLR4 mRNA, while Western blot (WB) was used to quantify TLR4 protein. Effects of LNG on normal endometrial stromal cells (ESCs) were evaluated. Suppression/over-expression vectors of lncRNA H19, miR-17, and TLR4 were constructed to observe their effects on ESCs. RESULTS: MiR-17 and TLR4 mRNA were up-regulated and lncRNA H19 was down-regulated in adenomyosis. After LNG treatment, lncRNA H19 was up-regulated while miR-17 and TLR4 were down-regulated. LNG, up-regulation of lncRNA H19, and down-regulation of miR-17 and TLR4 portend increased apoptosis, G1-arrested cells, as well as inhibited inflammation. Dual-luciferase reporter (DLR) assay conformed the targeting relation of lncRNA H19/miR-17/TLR4 pathway. CONCLUSION: LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway.
format Online
Article
Text
id pubmed-7457840
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74578402020-09-11 Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway Liang, Na Zhang, Wenfeng Wang, Hongjiang Shi, Wei Wang, Li Ma, Lijuan Drug Des Devel Ther Original Research PURPOSE: To explore the mechanism of levonorgestrel (LNG)-ameliorating adenomyosis through long non-coding RNA H19 (lncRNA H19)/miR-17/Toll-like receptor 4 (TLR4) pathway. PATIENTS AND METHODS: A total of 71 cases of adenomyosis and 54 cases of normal endometrium were sampled. Quantitative polymerase chain reaction (qPCR) was employed to quantify lncRNA H19, miR-17, and TLR4 mRNA, while Western blot (WB) was used to quantify TLR4 protein. Effects of LNG on normal endometrial stromal cells (ESCs) were evaluated. Suppression/over-expression vectors of lncRNA H19, miR-17, and TLR4 were constructed to observe their effects on ESCs. RESULTS: MiR-17 and TLR4 mRNA were up-regulated and lncRNA H19 was down-regulated in adenomyosis. After LNG treatment, lncRNA H19 was up-regulated while miR-17 and TLR4 were down-regulated. LNG, up-regulation of lncRNA H19, and down-regulation of miR-17 and TLR4 portend increased apoptosis, G1-arrested cells, as well as inhibited inflammation. Dual-luciferase reporter (DLR) assay conformed the targeting relation of lncRNA H19/miR-17/TLR4 pathway. CONCLUSION: LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway. Dove 2020-08-24 /pmc/articles/PMC7457840/ /pubmed/32921982 http://dx.doi.org/10.2147/DDDT.S248095 Text en © 2020 Liang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liang, Na
Zhang, Wenfeng
Wang, Hongjiang
Shi, Wei
Wang, Li
Ma, Lijuan
Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title_full Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title_fullStr Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title_full_unstemmed Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title_short Levonorgestrel Ameliorates Adenomyosis via lncRNA H19/miR-17/TLR4 Pathway
title_sort levonorgestrel ameliorates adenomyosis via lncrna h19/mir-17/tlr4 pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457840/
https://www.ncbi.nlm.nih.gov/pubmed/32921982
http://dx.doi.org/10.2147/DDDT.S248095
work_keys_str_mv AT liangna levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway
AT zhangwenfeng levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway
AT wanghongjiang levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway
AT shiwei levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway
AT wangli levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway
AT malijuan levonorgestrelamelioratesadenomyosisvialncrnah19mir17tlr4pathway